Physician profile
Joy Leblanc
NPI 1003811282
$2,631.45
in general payments reported to CMS, 2019-2025
31 companies · $80.04 in 2025
The $80.04 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $382 · 2021: $501 · 2022: $463 · 2023: $581 · 2024: $269 · 2025: $80.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $857 · Education: $72.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $857.47 |
| Education | $72.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $573.05 | 2019-2023 | |
| Astellas Pharma US INC | $341.28 | 2022-2024 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $299.77 | 2021-2024 | |
| Millicent US INC | $122.54 | 2019-2021 | |
| Therapeuticsmd, INC. | $111.38 | 2020-2022 | |
| Exeltis, USA INC. | $99.63 | 2020-2025 | Slynd |
| Biogen, INC. | $93.60 | 2024-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $88.95 | 2019-2023 | |
| Coopersurgical, INC. | $83.64 | 2019-2025 | Sos |
| Caldera Medical, INC | $79.50 | 2023 | Desara |
| Exact Sciences Corporation | $75.52 | 2023-2025 | Cologuard Collection Kit |
| Amag Pharmaceuticals, INC. | $74.32 | 2019-2020 | |
| Agile Therapeutics, INC. | $74.19 | 2021-2023 | Twirla |
| Aspira Women'S Health INC | $68.12 | 2020-2023 | Ova1 |
| Evofem Biosciences, INC. | $64.92 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $50.83 | 2019-2020 | |
| Lupin INC. | $41.18 | 2019-2020 | |
| Duchesnay USA Incorporated | $31.38 | 2019 | |
| Ascend Therapeutics US, LLC | $26.73 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $24.76 | 2024 | Myfembree |
| Avanos Medical | $23.40 | 2019 | |
| Renovia INC | $22.89 | 2019 | |
| Scynexis, INC. | $22.41 | 2022 | |
| Smith+Nephew, INC. | $21.82 | 2019 | |
| Myovant Sciences INC. | $19.73 | 2021 | |
| Medicem INC. | $18.72 | 2020 | |
| Sage Therapeutics, LLC | $17.12 | 2023 | |
| Avion Pharmaceuticals | $16.97 | 2021 | |
| Mylan Pharmaceuticals INC. | $16.40 | 2022 | |
| Merck Sharp & Dohme LLC | $15.51 | 2019 | |
| Covidien Lp | $11.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Leblanc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.